… Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity
after … variability in the prevention and treatment of GVHD worldwide. In 2014, to standardise …

… presented in an invitational expert meeting. Recommendations linked to human leukocyte
antigen similarity between donor … transplantation, donor lymphocyte infusion or treatment with …

… infusion of hematopoietic stem cells (HSCs) with the aim of restoring the bone marrow function
after administering a preparative treatment… acute and chronic GVHD is presented in Fig. 1. …

… host antigen-presenting cells and enhance their ability to present donor-recipient polymorphic
… A subsequent study combined donor lymphocyte infusion (DLI) with daily low-dose IL-2 in …

… + cells, and CD34 + cells infused in each cycle are presented in Supplementary Table 1. …
The treatment of acute GVHD (aGVHD) and cGVHD after Chemo-DLI was according to the …

… ruxolitinib is second-line treatment. No validated treatments are … presentation before 100
days after alloHCT and chronic GVHD was classified as symptom presentation >100 days after …

… after allo-HCT was terminated (NCT01747499). However, another trial evaluated effects of
azacitidine after donor lymphocyte infusion (DLI) for relapsed AML after … Here, we presented …

… Most patients presented these oral lesions concomitant with … The treatment of oral lesions
included high- to very high-… role of topical corticosteroids in the management of GVHD-related …

… donor leucocyte infusion (DLI). In order to obtain comparable data among GVHD categories,
episodes of GVHD occurring after a DLI administration … Data were presented as median and …

… The presentation of these proteins is done after a process … or treatment which are discussed
throughout this manuscript. … In both studies donor lymphocyte infusions were used to …